Clinical Trial Update: EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients [Phase 2]

View source ↗

Summary

This document notes the completion of a Phase 2 trial of EndoTAG-1 in patients with triple-negative breast cancer. The study sponsor is MediGene.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• EndoTAG-1

Snippet

Sponsor: MediGene | Conditions: Breast Neoplasms | Phase 2 | Status: COMPLETED